TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01889186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199 (Main Cohort)
Description: Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199 (Safety Expansion Cohort)
Description: Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.
Study: NCT01208298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Sore Patch
Description: All eligible subjects received CSP-Night at Screening Visit 1. Subjects were instructed to initiate therapy within approximately 1 hour of onset of their first sign or symptom. Treatment was continued until the lesion healed, or for a maximum of 10 days. All subjects were expected to return to the study center for clinical assessments within 24 hours and 48 hours after initiating treatment, and every other day thereafter, with a final visit at Day 10 or at the time of completion/ discontinuation if before Day 10.
Study: NCT01166516

Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment with HUD IBV Valve System
Description: Treatment involves placing one or more valves in the airways of the lung to control a prolonged air leak.
Study: NCT03262740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986195
Description: Oral administration of specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Description: Oral Contraceptive
Study: NCT00286117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: oral
Study: NCT03956290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TREAT pilot intervention
Description: Participants will be asked to use the app and take pictures of everything they eat and drink, from the time they get up to the time they go to bed, regardless of size of meal/snacks/drink, for 2 weeks. This will generate data on their eating pattern and eating duration. Participants will be reminded through app, call or text by study staff based on personalized eating schedule. The sleep schedule will also be recorded.
Study: NCT03364855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Star excursion balance test
Description: Star excursion balance test,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesthetic Ability Trainer 2000
Description: Kinesthetic Ability Trainer 2000

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SEBT and KAT 2000
Description: Star excursion balance test and Kinesthetic Ability Trainer 2000
Study: NCT01933451

Intervention type: OTHER
Group type: OTHER
Intervention: Intraoperative fluid therapy
Description: Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative fluid therapy
Description: Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
Study: NCT01227603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine-candesartan FDC (BAY 98-7106)
Description: Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine GITS (Adalat LA, BAYA1040)
Description: Single oral dose of 1 tablet of nifedipine GITS 60 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine GITS (Adalat LA, BAYA1040)
Description: Single oral dose of 1 tablet of nifedipine GITS 60 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan (Atacand)
Description: Single oral dose of 32 mg (2 x 16 mg tablet) candesartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan (Atacand)
Description: Single oral dose of 32 mg (2 x 16 mg tablet) candesartan
Study: NCT00732186

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
Study: NCT01321541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pixantrone + Rituximab
Description: Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Rituximab
Description: Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
Study: NCT04496999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: Dose level 0: HDM201 40 mg QD d1,2 (midday)/ Dose level 1: HDM201 40 mg QD d1,2,3 (midday) = Starting dose/ Dose level 2: HDM201 40 mg QD d1,2,3,4,5 (midday)/ Dose level 3: HDM201 60 mg QD d1,2,3,4,5 (midday)/ Dose level 4: HDM201 80 mg QD d1,2,3,4,5 (midday)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 50mg bid d1-28 (morning, evening)
Study: NCT04131530

Intervention type: DIAGNOSTIC_TEST
Intervention: The diagnosis of Artificial Intelligence and endoscopist
Description: When the colon mucosa is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
Study: NCT03223532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PrePex Day 7 FRP
Description: Standard PrePex procedure, foreskin and device are removed 1 week after device application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex Day 0 FRP
Description: Removal of the foreskin shortly after device application, the device is removed 1 week later
Study: NCT01938430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose
Study: NCT00688285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: automated clinical alerts
Description: automated clinical alerts in the electronic medical record

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: provider education
Description: PCP education session on CKD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: provider education
Description: PCP education session on CKD
Study: NCT03842943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Preoperative infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Preoperative intralesional injection
Study: NCT01051609

Intervention type: OTHER
Intervention: History and Physical Exam
Description: The physical exam includes vital signs and ECOG performance status.
Study: NCT03554148

Intervention type: OTHER
Intervention: No intervention
Description: This is purely an observational study. Groups SSI/No SSI are defined by the occurence of a surgical site infection.

Intervention type: OTHER
Intervention: No intervention
Description: This is purely an observational study. Groups SSI/No SSI are defined by the occurence of a surgical site infection.
Study: NCT01625819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: 32 1-hour bi-weekly group sessions of Tai Chi instruction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Band
Description: 32 1-hour bi-weekly group sessions of Resistance Band exercises

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: 32 1-hour bi-weekly group sessions of health education
Study: NCT03586505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light exposure
Description: The 6 lights used randomly are :~* 482nm =standard blue light illumination,~* 650nm,~* 675nm,~* 700nm,~* 750nm~* 800nm
Study: NCT00462592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: inhaled budesonide turbuhaler 200ug taken 1 puff morning \& 1 puff evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: inhaled budesonide turbuhaler 200ug taken 1 puff morning \& 1 puff evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: montelukast 5 mg ( \< 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: montelukast 5 mg ( \< 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03738839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantitative Light-Induced Fluorescence
Description: White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantitative Light-Induced Fluorescence
Description: White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Light-Induced Fluorescence
Description: White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.
Study: NCT00462592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04447027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin (12mg/ m2 ) will be administered on days 1 and 10 of each cycle through a peripheral or central intravenous catheter for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin (12mg/ m2 ) will be administered on days 1 and 10 of each cycle through a peripheral or central intravenous catheter for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered by oral intake in a dose-escalation with a starting dose of 5mg daily, a second dose level of 10mg daily, a third dose level at 15mg daily, and a fourth dose level at 20mg daily on days -7 to day 10 of first cycle. After the second cycle, lenalidomide will be given from day 1 to day 10 in each cycle for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered by oral intake in a dose-escalation with a starting dose of 5mg daily, a second dose level of 10mg daily, a third dose level at 15mg daily, and a fourth dose level at 20mg daily on days -7 to day 10 of first cycle. After the second cycle, lenalidomide will be given from day 1 to day 10 in each cycle for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486 (5-azacitidine)
Description: CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486 (5-azacitidine)
Description: CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 40mg, PO, will be given on days 1 and 10 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 40mg, PO, will be given on days 1 and 10 of each cycle.
Study: NCT03779750

Intervention type: DIAGNOSTIC_TEST
Intervention: s.creatinine
Description: All ESRD patients on regular hemodialysis in dialysis unit of Assiut university Hospital duing one year. will be subjected to 3- Routine investigations including complete blood picture ,blood urea , s.creatinine,urine analysis , calcium, phosphorus, and parathyroid hormone.
Study: NCT01803217

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function
Study: NCT04019340

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Usual care as described for the CG will also be provided to the IG. Wound size measurement, wound care, and questionnaires will be provided by the institute's nurses. Usual care will be enhanced by a pluridisciplinary educational program
Study: NCT01250873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: po administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: po administration
Study: NCT00112528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT01559350

Intervention type: PROCEDURE
Intervention: A right gastroepiploic artery in situ grafting
Description: A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB

Intervention type: PROCEDURE
Intervention: A saphenous vein grafting
Description: A saphenous vein grafting in the right coronary artery system during OPCAB
Study: NCT03738839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct bonding
Description: The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct bonding
Description: The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.
Study: NCT02176863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flebogamma 5% DIF
Description: Human plasma-derived immunoglobulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flebogamma 5% DIF
Description: Human plasma-derived immunoglobulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flebogamma 5% DIF
Description: Human plasma-derived immunoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution
Study: NCT03179020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist use
Description: Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Management of the potential donor according usual care.
Study: NCT03449329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SIP
Description: The intervention group will receive a SIP block

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SIP
Description: The intervention group will receive a SIP block
Study: NCT03121196

Intervention type: OTHER
Intervention: Epices score
Description: Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression

Intervention type: OTHER
Intervention: Epices score
Description: Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression
Study: NCT03050853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: The e-cigarette arm will be provided with 8 weeks of free e-cigarettes based on self-report of regular tobacco use. Participants assigned in this arm will be asked to switch combustible tobacco with e-cigarettes. The appeal of e-cigarettes and health impacts will be measured, but we are not targeting quitting combustible tobacco or reducing craving.
Study: NCT03847753

Intervention type: OTHER
Intervention: Organic Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study: NCT01051609

Intervention type: OTHER
Intervention: Grip Strength Measurement
Description: A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.

Intervention type: OTHER
Intervention: Blood Collection
Description: A set of blood markers will be assayed at baseline, 6 months, and 12 months.

Intervention type: PROCEDURE
Intervention: Ultrasound of Hand/Wrist
Description: An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
Study: NCT03738839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect bonding
Description: For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect bonding
Description: For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.
Study: NCT02348684

Intervention type: RADIATION
Intervention: Radiation therapy groups
Description: Radiation Therapy treatment between 2000 and 2007.
Study: NCT02307201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The patient will receive magnesium sulfate for 24 hours postpartum
Study: NCT00977756

Intervention type: DRUG
Intervention: Raltegravir (RAL)
Description: 400 mg twice daily (BID)

Intervention type: DRUG
Intervention: Raltegravir (RAL)
Description: 400 mg twice daily (BID)

Intervention type: DRUG
Intervention: Raltegravir (RAL)
Description: 400 mg twice daily (BID)

Intervention type: DRUG
Intervention: Atazanavir (ATV)
Description: 300 mg daily
Study: NCT01095003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine plus Capecitabine
Description: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
Study: NCT04122222

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.
Study: NCT02771665

Intervention type: OTHER
Intervention: Mammographic breast density at diagnosis
Description: Mammographic breast density at diagnosis

Intervention type: OTHER
Intervention: Mammographic breast density at diagnosis
Description: Mammographic breast density at diagnosis
Study: NCT01191021

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol Anesthesia
Description: Volunteers will undergo propofol anesthesia for 90 min.
Study: NCT01241942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steen Solution™
Description: This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNC Hospitals (UNCH) where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNCH based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Lung Transplant
Description: No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
Study: NCT03468036

Intervention type: OTHER
Intervention: none, does not apply
Description: none: does not apply

Intervention type: OTHER
Intervention: none, does not apply
Description: none: does not apply
Study: NCT03152461

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.